Ownership and insider activity for Celularity Inc. (CELU): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking.
Price
| Price | $1.29 |
| Market Cap | $37M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-19 | Philip & Daniele Barach Family Trust | J-Other | 1,204,819 | $2.0M |
| 2026-06-19 | Philip & Daniele Barach Family Trust | J-Other | 839,160 | $1.7M |
| 2026-06-19 | Barach Philip Alan | J-Other | 1,204,819 | $2.0M |
| 2026-06-19 | Barach Philip Alan | J-Other | 839,160 | $1.7M |
| 2026-06-19 | Barach Daniele Wolf | J-Other | 1,204,819 | $2.0M |
| 2026-06-19 | Barach Daniele Wolf | J-Other | 839,160 | $1.7M |
| 2025-12-19 | Barach Philip Alan | 1,204,819 | $2.0M | |
| 2026-06-19 | Barach Philip Alan | 839,160 | $1.7M | |
| 2025-12-19 | Barach Daniele Wolf | 1,204,819 | $2.0M | |
| 2026-06-19 | Barach Daniele Wolf | 839,160 | $1.7M |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24707 | $28.1M | $54.3M | $37.2M | $14.0M | $227000 | $738000 | $6.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $3.9M | $3.1M | $6.5M | $5.2M | $7.0M | $12.1M | $13.6M | $4.7M |
| Inventory | $3.5M | $3.2M | $3.9M | $9.5M | $5.3M | $5.8M | $5.4M | $571000 |
| Total Current Assets | $24707 | $36.8M | $72.2M | $59.1M | $33.5M | $19.8M | $20.6M | $12.3M |
| Property, Plant & Equipment | $4.0M | $66.4M | $90.1M | $90.6M | $88.7M | $78.8M | $72.4M | $66.5M |
| Goodwill | $130.6M | $127.1M | $123.3M | $123.3M | $119.7M | $7.3M | $7.3M | $7.3M |
| Intangible Assets | $393.7M | $271.5M | $125.4M | $123.2M | $121.0M | $11.0M | $9.2M | $7.8M |
| Total Assets | $24707 | $521.5M | $431.0M | $414.1M | $401.1M | $143.9M | $132.7M | $107.3M |
| Accounts Payable | $5.3M | $18883 | $5.4M | $9.3M | $5.8M | $14.1M | $23.3M | $26.4M |
| Short-term Debt | 0 | 0 | $3.0M | $3.1M | $37.6M | $39.2M | $6.4M | $14.0M |
| Total Current Liabilities | $150555 | $20.6M | $26.7M | $26.2M | $62.1M | $67.3M | $53.7M | $80.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $35.9M | 0 |
| Total Liabilities | $150555 | $383.6M | $412.3M | $314.7M | $202.2M | $102.9M | $123.8M | $145.4M |
| Retained Earnings | -$1098 | -$355.3M | -$563.6M | -$663.7M | -$645.5M | -$841.8M | -$899.7M | -$991.5M |
| Total Equity | -$125847 | $137.9M | $18.7M | $99.4M | $198.9M | $41.0M | $8.8M | -$38.1M |
| Total Debt | $150000 | $28.1M | $30.6M | $31.1M | $65.6M | $65.4M | $68.8M | $40.9M |
| Net Debt | $125293 | -$66000 | -$23.7M | -$6.1M | $51.6M | $65.2M | $68.1M | $34.7M |
| Working Capital | -$125848 | $16.2M | $45.5M | $32.9M | -$28.6M | -$47.5M | -$33.1M | -$68.4M |
Financial Health
| Debt / Equity | -1.07 |
| Current Ratio | 0.15 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -15.22 |
Profitability
| Return on Equity | 411.46% |
| Return on Invested Capital | -151.11% |
| Return on Assets | -85.45% |
| Gross Margin | 76.04% |
| Operating Margin | -230.92% |
| Net Margin | -345.44% |
Related companies: ANVS · ATNM · BCAB · BTAI · FGEN · GBIO · KZR
Explore sector: Healthcare · Biotechnology
More sections of CELU: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks